Abstract
We describe the use of abciximab to prevent rethrombosis of the basilar artery after transluminal angioplasty. A 60-year-old patient with vertebral basilar insufficiency and acute occlusion of the basilar artery underwent revascularization with urokinase and angioplasty. Despite the repeated use of urokinase and angioplasty under anticoagulation with heparin, the basilar artery immediately rethrombosed. In a final attempt to prevent rethrombosis, abciximab was administered before the final angioplasty, resulting in a widely patent basilar artery and no rethrombosis.
MeSH terms
-
Abciximab
-
Angioplasty, Balloon*
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / therapeutic use*
-
Basilar Artery* / diagnostic imaging
-
Cerebral Angiography
-
Combined Modality Therapy
-
Follow-Up Studies
-
Heparin / adverse effects
-
Heparin / therapeutic use
-
Heparin, Low-Molecular-Weight / administration & dosage
-
Heparin, Low-Molecular-Weight / adverse effects
-
Humans
-
Immunoglobulin Fab Fragments / adverse effects
-
Immunoglobulin Fab Fragments / therapeutic use*
-
Intracranial Embolism and Thrombosis / blood
-
Intracranial Embolism and Thrombosis / diagnostic imaging
-
Intracranial Embolism and Thrombosis / therapy*
-
Male
-
Middle Aged
-
Platelet Aggregation Inhibitors / adverse effects
-
Platelet Aggregation Inhibitors / therapeutic use*
-
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*
-
Platelet Glycoprotein GPIIb-IIIa Complex / physiology
-
Recurrence
-
Retreatment
-
Thrombolytic Therapy
-
Urokinase-Type Plasminogen Activator / adverse effects
-
Urokinase-Type Plasminogen Activator / therapeutic use
Substances
-
Antibodies, Monoclonal
-
Heparin, Low-Molecular-Weight
-
Immunoglobulin Fab Fragments
-
Platelet Aggregation Inhibitors
-
Platelet Glycoprotein GPIIb-IIIa Complex
-
Heparin
-
Urokinase-Type Plasminogen Activator
-
Abciximab